Spondylitis News and Research

RSS

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.

10 Nov 2019

Updated recommendations for treatment of patients with axial spondyloarthritis released

Today, the American College of Rheumatology, in partnership with the Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network, released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

22 Aug 2019

IMAS survey reveals 74% of people living with axial spondyloarthritis struggle to find a job

The European results of the International Map of Axial Spondyloarthritis reveal that people living with axial spondyloarthritis (axSpA) – a long-term inflammatory spine condition which is as prevalent as rheumatoid arthritis – face uncertainty and worry for their future, with 74% reporting difficulties finding a job due to the condition.

From Novartis 13 Jun 2019

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

28 Mar 2019

ACR and NPF release joint treatment guideline for psoriatic arthritis

The American College of Rheumatology and National Psoriasis Foundation have released a joint treatment guideline for psoriatic arthritis that provides evidence-based pharmacologic and non-pharmacologic recommendations on caring for treatment-naïve patients with active PsA and patients who continue to have active PsA despite treatment.

4 Dec 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

MSU researchers move one step closer to solving arthritic disease in teenagers

A new Michigan State University study has found that a malfunctioning gene associated with a common arthritic disease that often starts in teenagers is now directly linked to the loss of vital immune cells that may prevent it.

24 Aug 2018

Researchers discover new protein that controls level of inflammation-inducing molecule

One of the major therapeutic targets for inflammatory diseases is the inflammation-inducing molecule TNF. However, excess levels of TNF cause side effects and can lead to diseases.

27 Jul 2018

Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future

A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis every year in the United States, affecting 2.2% of the population.

20 Jun 2018

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Celecoxib combined with TNF inhibitors was associated with the greatest reduction in radiographic progression.

14 Jun 2018

Price check on drug ads: Would revealing costs help patients control spending?

President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.

6 Jun 2018

New study launched to examine effects of rheumatologic agent on bone health

Researchers at Hospital for Special Surgery have launched a pilot study to see how a drug that treats several related autoimmune disorders affects the skeleton.

7 May 2018

Online consultation via mobile app reduces costs and delays for rheumatic disease patients

Researchers in China have developed a new online consultation tool for rheumatic disease patients, which may strengthen the interaction between doctors and patients and lead to more efficient management of chronic illness, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.

16 Jun 2017

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug-target binding in a physiological environment and at clinically-relevant concentrations.

15 May 2017

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints®, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy and patient-centered research, today announced the publication of “Raising the Voice of the Patients: A Patient’s Guide to Living with Rheumatoid Arthritis”.

25 Jan 2017

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy, and patient-centered research, today announced the forthcoming publication of “A Patient’s Guide to Living with Rheumatoid Arthritis.”

15 Nov 2016

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016